Your session is about to expire
← Back to Search
Immunotherapy + TACE +/- Lenvatinib for Liver Cancer (EMERALD-3 Trial)
EMERALD-3 Trial Summary
This trial will test a new combination therapy for liver cancer.
EMERALD-3 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowEMERALD-3 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 80 Patients • NCT03015129EMERALD-3 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have had serious heart problems like heart failure, chest pain, or irregular heartbeat.My cancer has not spread outside my liver.My liver function is good.I am co-infected with both Hepatitis B and D.My high blood pressure is not under control.I am fully active or restricted in physically strenuous activity but can do light work.I have had episodes of brain confusion due to liver problems.My organs and bone marrow are working well.My condition cannot be cured with surgery or transplantation, but can be treated with TACE.
- Group 1: Arm A
- Group 2: Arm B
- Group 3: Arm C
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does this test include people who are not yet 60 years old?
"Eligibility for this clinical trial includes patients between 18 and 120 years old. There are 84 trials for minors and 2654 for senior citizens."
What is the official verdict from the FDA on Durvalumab?
"There is a solid body of evidence, from both Phase 3 clinical trials and additional research, suggesting that Durvalumab is a safe medication."
Who does this research project target as test subjects?
"This study is looking for 525 participants that have liver carcinoma, are between 18 and 120 years old, and also meet the following requirements: no evidence of extrahepatic disease, disease not curable through surgery or transplant but treatable through TACE, Child Pugh score of A, ECOG performance status of 0 or 1, measurable disease by mRECIST criteria, and adequate organ and marrow function."
Does this experiment still require more participants?
"That is accurate, the information available on clinicaltrials.gov does show that this study is still recruiting patients. This particular trial was first made public on March 28th, 2022 and the most recent update was on September 27th, 2022. In total, they are looking for 525 individuals to participate across 10 different sites."
How many people are participating in this test to find out if the new medication is effective?
"Yes, the information on clinicaltrials.gov indicates that this clinical trial is currently seeking candidates. The trial was initially posted on 3/28/2022 and was last updated on 9/27/2022. The study is recruiting for 525 patients at 10 locations."
Yes, the clinical trial is being run at multiple locations in Canada.
"To minimize participant burden, the team running this study has chosen to set up shop in 10 locations spread out over Baltimore, Montreal, Ottawa, and 10 other cities."
Share this study with friends
Copy Link
Messenger